International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 775-781 , 1 March 2010

Influence of Technologic Advances on Outcomes in Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy

  • Zhongxing X. Liao, M.D.

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationReprint requests to: Zhongxing X. Liao, M.D., 1515 Holcombe Blvd, Unit 97, Houston, TX 77030. Tel: (713) 563-2300; Fax: (713) 563-1331
    • ,
  • Ritsuko R. Komaki, M.D.

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Howard D. Thames Jr., Ph.D.

      Affiliations

    • Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Helen H. Liu, Ph.D.

      Affiliations

    • Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Susan L. Tucker, Ph.D.

      Affiliations

    • Department of Bioinformatics and Computational Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Radhe Mohan, Ph.D.

      Affiliations

    • Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Mary K. Martel, Ph.D.

      Affiliations

    • Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Xiong Wei, M.D.

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Kunyu Yang, M.D.

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Edward S. Kim, M.D.

      Affiliations

    • Department of Head and Neck/Thoracic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • George Blumenschein, M.D.

      Affiliations

    • Department of Head and Neck/Thoracic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Waun Ki Hong, M.D.

      Affiliations

    • Department of Head and Neck/Thoracic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • James D. Cox, M.D.

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Received 1 April 2008 ,Revised 15 November 2008 ,Accepted 17 February 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Wagner H, Wagner H. Image-guided conformal radiation therapy planning and delivery for non-small-cell lung cancer. Cancer Control. 2003;10:277–288
  3. Mell LK, Mehrotra AK, Mundt AJ, et al. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer. 2005;104:1296–1303
  4. Paliwal BR, Brezovich IA, Hendee WR. IMRT may be used to excess because of its higher reimbursement from medicare. Med Phys. 2004;31:1–3
  5. Giraud P, Helfre S, Lavole A, et al. [Non-small-cell bronchial cancers: Improvement of survival probability by conformal radiotherapy]. Cancer Radiother. 2002;6(Suppl 1):125s–134s
  6. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:94–102
  7. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT) [published erratum appears in Int J Radiat Oncol Biol Phys 2007;67:1606]. Int J Radiat Oncol Biol Phys. 2006;66:1399–1407
  8. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–526
  9. Murshed H, Liu HH, Liao Z, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer [published erratum appears in Int J Radiat Oncol Biol Phys 2004;59:921]. Int J Radiat Oncol Biol Phys. 2004;58:1258–1267
  10. Liu HH, Wang X, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1268–1279
  11. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys. 2003;55:724–735
  12. Nutting CM, Corbishley CM, Sanchez-Nieto B, et al. Potential improvements in the therapeutic ratio of prostate cancer irradiation: Dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol. 2002;75:151–161
  13. Chao K, Majhail N, Huang C, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques. Radiother Oncol. 2001;61:275–280
  14. Hong L, Alektiar KM, Hunt M, et al. Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh. Int J Radiat Oncol Biol Phys. 2004;59:752–759
  15. Milano MT, Chmura SJ, Garofalo MC, et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2004;59:445–453
  16. Mundt A, Mell L, Roeske J. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2003;56:1354–1360
  17. Kupelian P, Reddy C, Carlson T, et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:904–912
  18. Zelefsky M, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;52:1111–1116
  19. Knab BR, Roeske JC, Mehta N, et al. Outcome of endometrial cancer patients treated with adjuvant intensity modulated pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2004;60:S303–S304
  20. Uy NW, Woo SY, Teh BS, et al. Intensity-modulated radiation therapy (IMRT) for meningioma. Int J Radiat Oncol Biol Phys. 2002;53:1265–1270
  21. Chang JY, Liu HH, Komaki R, et al. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep. 2005;7:255–259
  22. Gierga DP, Chen GTY, Kung JH, et al. Quantification of respiration-induced abdominal tumor motion and its impact on IMRT dose distributions. Int J Radiat Oncol Biol Phys. 2004;58:1584–1595
  23. Chui C, Yorke E, Hong L. The effects of intra-fraction organ motion on the delivery of intensity-modulated field with a multileaf collimator. Med Phys. 2003;30:1736–1746
  24. Bortfeld T, Jokivarsi K, Goitein M, et al. Effects of intra-fraction motion on IMRT dose delivery: Statistical analysis and simulation. Phys Med Biol. 2002;47:2203–2220
  25. Brenner DJ, Doll R, Goodhead DT, et al. Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know. Proc Natl Acad Sci U S A. 2003;100:13761–13766
  26. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1–7
  27. Palta JR, Deye JA, Ibbott GS, et al. Credentialing of institutions for IMRT in clinical trials. Int J Radiat Oncol Biol Phys. 2004;59:1257–1259author reply 1259–1261
  28. NCI. NCI Guidelines on the Use of IMRT in Clinical Trials; 2002.
  29. Feinstein F, Sosin D, Wells C. The Will Rogers phenomenon. Stage migration and new diagnostic technoniques as a source of misleading statitics for survival in cancer. N Engl J Med. 1985;312:1604–1608
  30. Morgensztern D, Goodgame B, Baggstrom M, et al. The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol. 2008;3:135–139

 Conflict of interest: none.

PII: S0360-3016(09)00322-8

doi: 10.1016/j.ijrobp.2009.02.032

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3 , Pages 775-781 , 1 March 2010

Article Tools

* Image Usage & Resolution